Abstract #0501

Multimodal Imaging of Vascularity and Drug Delivery in GBM Patients Treated with Anti-angiogenesis Inhibitor

Yi-Fen Yen¹, Jayashree Kalpathy-Cramer¹, Ciprian Catana¹, Xiao Da², Yangming Ou¹, Andrew L. Beers¹, Jacob Hooker¹, Bruce Rosen¹, Tracy Batchelor³, and Elizabeth R. Gerstner³

¹Athinoula A. Martinos Center for Biomedical Imaging, Massachusetts General Hospital, Charlestown, MA, United States, ²Functional Neuroimaging Laboratory, Brigham and Women’s Hospital, Boston, MA, United States, ³Department of Neuro-oncology, Massachusetts General Hospital, Boston, MA, United States

Anti-angiogenic agents can decrease vessel permeability and perfusion, raising concerns that these agents may also decrease blood brain barrier penetration of concomitantly administered chemotherapy. Using MR-PET multimodal imaging, we found radiolabeled temozolomide correlated with permeability and perfusion in patients with recurrent GBM treated with bevacizumab. MR assessment of vascularity may be a surrogate marker for concomitant drug delivery.

This abstract and the presentation materials are available to members only; a login is required.

Join Here